Bioniche Life Scienc (BNHLF) 0.1024 $BNHLF
Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
PR Newswire - Wed Aug 24, 5:00AM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that it has executed a binding Agreement, subject to shareholder approval, to be acquired by ProMetic Life Sciences Inc. for consideration of $0.14/Telesta share, payable in freely tradable shares of ProMetic Life Sciences (TSX: PLI). The actual number of ProMetic shares payable per Telesta common share, will be calculated based on the 5-day volume-weighted average price of ProMetic shares, for the 5 days immediately preceding the date on which the Court ordered plan of arrangement becomes effective if shareholders vote to approve this transaction.
TST.TO: 0.13 (-0.01), PLI.TO: 2.80 (unch)
ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction
PR Newswire - Wed Aug 24, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it has entered into a binding agreement (the "Agreement" for the acquisition of Telesta Therapeutics, Inc, ("Telesta" by way of a plan of arrangement under the Canada Business Corporations Act (the "Acquisition".
PLI.TO: 2.80 (unch)
Telesta Therapeutics Provides Strategic Update
CNW Group - Tue Aug 02, 6:00AM CDT
Telesta Therapeutics Inc. (TSX: TST)(PNK: BNHLF) Telesta Therapeutics today announced concrete actions and decisions stemming from its ongoing strategic review process focussed on preserving shareholder capital and growing shareholder value. These decisions and actions can be summarized as follows:
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Publishes its Q3, 2016 Financial Statements and Provides Corporate Updates
CNW Group - Tue May 10, 6:00AM CDT
(Canadian dollars, except where noted)
TST.TO: 0.13 (-0.01)
Telesta Announces Type A Meeting Results and Strategic Option Review
PR Newswire - Mon Apr 18, 6:00AM CDT
Telesta Therapeutics Inc. (Telesta) today announced the outcome of its Type A meeting with the U.S. Food and Drug Administration (FDA), which was held via teleconference on Friday, April 15th. Telesta's questions for this meeting were centered on whether the FDA would permit Telesta to resubmit their BLA for MCNA1 under Accelerated Approval, with a more restricted label. Based on their review of Telesta's regulatory filing and the additional information provided by Telesta in the briefing package prepared for the Type A meeting, the FDA has ruled that any potential commercial approval of MCNA would require an additional Phase 3 clinical trial to be completed prior to resubmission of the MCNA BLA.
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Corporate Update - Type A Meeting with the FDA Scheduled
PR Newswire - Tue Apr 12, 3:30PM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that a Type A meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on Friday, April 15, 2016. This Type A meeting will be focused on the FDA's responses to Telesta's questions concerning the regulatory pathway forward for approval of MCNA1 in the United States.
TST.TO: 0.13 (-0.01)
IIROC Trade Resumption - Telesta Therapeutics Inc.
Newsfile Corp - Tue Feb 02, 11:15AM CST
Trading resumes in:
IIROC Trade Resumption - TST
CNW Group - Tue Feb 02, 11:15AM CST
Trading resumes in:
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Receives Complete Response Letter from FDA
PR Newswire - Tue Feb 02, 11:01AM CST
Telesta Therapeutics Inc. (TSX:TST) (PNK:BNHLF) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to Telesta's Biologics License Application (BLA) for MCNA1. In this letter, the FDA communicated that an additional Phase 3 clinical trial for MCNA would be necessary to adequately establish MCNA's efficacy and safety. The FDA also encouraged Telesta to meet with them to discuss further clinical development of MCNA.
TST.TO: 0.13 (-0.01)
IIROC Trade Halt - Telesta Therapeutics Inc.
Newsfile Corp - Tue Feb 02, 7:28AM CST
The following issues have been halted by IIROC:
Telesta Therapeutics Corporate Update
PR Newswire Europe - Mon Dec 14, 6:02AM CST
MONTREAL, December 14, 2015 /PRNewswire/ --
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
PR Newswire - Wed Aug 24, 5:00AM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that it has executed a binding Agreement, subject to shareholder approval, to be acquired by ProMetic Life Sciences Inc. for consideration of $0.14/Telesta share, payable in freely tradable shares of ProMetic Life Sciences (TSX: PLI). The actual number of ProMetic shares payable per Telesta common share, will be calculated based on the 5-day volume-weighted average price of ProMetic shares, for the 5 days immediately preceding the date on which the Court ordered plan of arrangement becomes effective if shareholders vote to approve this transaction.
TST.TO: 0.13 (-0.01), PLI.TO: 2.80 (unch)
ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction
PR Newswire - Wed Aug 24, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it has entered into a binding agreement (the "Agreement" for the acquisition of Telesta Therapeutics, Inc, ("Telesta" by way of a plan of arrangement under the Canada Business Corporations Act (the "Acquisition". PLI.TO: 2.80 (unch)
Telesta Therapeutics Provides Strategic Update
CNW Group - Tue Aug 02, 6:00AM CDT
Telesta Therapeutics Inc. (TSX: TST)(PNK: BNHLF) Telesta Therapeutics today announced concrete actions and decisions stemming from its ongoing strategic review process focussed on preserving shareholder capital and growing shareholder value. These decisions and actions can be summarized as follows:
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Publishes its Q3, 2016 Financial Statements and Provides Corporate Updates
CNW Group - Tue May 10, 6:00AM CDT
(Canadian dollars, except where noted)
TST.TO: 0.13 (-0.01)
Telesta Announces Type A Meeting Results and Strategic Option Review
PR Newswire - Mon Apr 18, 6:00AM CDT
Telesta Therapeutics Inc. (Telesta) today announced the outcome of its Type A meeting with the U.S. Food and Drug Administration (FDA), which was held via teleconference on Friday, April 15th. Telesta's questions for this meeting were centered on whether the FDA would permit Telesta to resubmit their BLA for MCNA1 under Accelerated Approval, with a more restricted label. Based on their review of Telesta's regulatory filing and the additional information provided by Telesta in the briefing package prepared for the Type A meeting, the FDA has ruled that any potential commercial approval of MCNA would require an additional Phase 3 clinical trial to be completed prior to resubmission of the MCNA BLA.
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Corporate Update - Type A Meeting with the FDA Scheduled
PR Newswire - Tue Apr 12, 3:30PM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that a Type A meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on Friday, April 15, 2016. This Type A meeting will be focused on the FDA's responses to Telesta's questions concerning the regulatory pathway forward for approval of MCNA1 in the United States.
TST.TO: 0.13 (-0.01)
IIROC Trade Resumption - Telesta Therapeutics Inc.
Newsfile Corp - Tue Feb 02, 11:15AM CST
Trading resumes in:
IIROC Trade Resumption - TST
CNW Group - Tue Feb 02, 11:15AM CST
Trading resumes in:
TST.TO: 0.13 (-0.01)
Telesta Therapeutics Receives Complete Response Letter from FDA
PR Newswire - Tue Feb 02, 11:01AM CST
Telesta Therapeutics Inc. (TSX:TST) (PNK:BNHLF) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to Telesta's Biologics License Application (BLA) for MCNA1. In this letter, the FDA communicated that an additional Phase 3 clinical trial for MCNA would be necessary to adequately establish MCNA's efficacy and safety. The FDA also encouraged Telesta to meet with them to discuss further clinical development of MCNA.
TST.TO: 0.13 (-0.01)
IIROC Trade Halt - Telesta Therapeutics Inc.
Newsfile Corp - Tue Feb 02, 7:28AM CST
The following issues have been halted by IIROC:
Telesta Therapeutics Corporate Update
PR Newswire Europe - Mon Dec 14, 6:02AM CST
MONTREAL, December 14, 2015 /PRNewswire/ --
TST.TO: 0.13 (-0.01)
